Research Summary

Dr. Cheryl Peretz is a pediatric hematologist-oncologist who provides care for many types of cancer in children. She specializes in difficult-to-treat blood cancers.

In research, Peretz focuses on myeloid leukemia, primarily acute myeloid leukemia (AML). Her studies also investigate mixed phenotype acute leukemia (a rare form of leukemia that combines AML and acute lymphoblastic leukemia) and other leukemias in which there is a genetic predisposition. She is particularly interested in how genetic alterations make some leukemias resist standard treatments.

Education

  • University of Pennsylvania, BA, 2008, Biological Basis of Behavior, Hispanic Studies
  • University of Connecticut, MD, 2012, Medicine
  • University of California San Francisco, Residency, 2015, Pediatrics
  • Children’s Hospital and Research Center, Oakland, Fellowship, 2019, Pediatric Hematology / Oncology
  • University of California San Francisco, Post-doc, 2022, AML

Honors & Awards

  • 2021
    ASH Abstract Achievement Award
  • 2019
    ASH Abstract Achievement Award
  • 2013
    Julius R. Kravens Award for Clinical Excellence, University of California San Francisco
  • 2011
    Gold Humanism Honor Society
  • 2009
    Pi Gamma Mu Honor Society of the Social Sciences

Selected Publications

  1. Peretz CAC, Kennedy VE, Walia A, Delley CL, Koh A, Tran E, Clark IC, Hayford CE, D'Amato C, Xue Y, Fontanez KM, May-Zhang AA, Smithers T, Agam Y, Wang Q, Dai HP, Roy R, Logan AC, Perl AE, Abate A, Olshen A, Smith CC. Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia. Nat Commun. 2024 Sep 18; 15(1):8191.  View on PubMed
  2. Wintering A, Hecht A, Meyer J, Wong EB, Hübner J, Abelson S, Feldman K, Kennedy VE, Peretz CAC, French DL, Maguire JA, Jobaliya C, Vasquez MR, Desai S, Dulman R, Nemecek E, Haines H, Hammad M, El Haddad A, Kogan SC, Abdullaev Z, Chehab FF, Tasian SK, Smith CC, Loh ML, Stieglitz E. LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia. Haematologica. 2024 08 01; 109(8):2533-2541.  View on PubMed
  3. Popescu B, Stahlhut C, Tarver TC, Wishner S, Lee BJ, Peretz CAC, Luck C, Phojanakong P, Camara Serrano JA, Hongo H, Rivera JM, Xirenayi S, Chukinas JA, Steri V, Tasian SK, Stieglitz E, Smith CC. Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. Cell Rep Med. 2023 11 21; 4(11):101290.  View on PubMed
  4. Joshi SK, Pittsenbarger J, Kennedy VE, Peretz CAC, Perl AE, Smith CC, Tyner JW, Druker BJ, Traer E. The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. Am J Hematol. 2023 12; 98(12):E364-E368.  View on PubMed
  5. Peretz CAC, Kennedy VE, Walia A, Delley CL, Koh A, Tran E, Clark IC, Hayford CE, D'Amato C, Xue Y, Fontanez KM, Roy R, Logan AC, Perl AE, Abate A, Olshen A, Smith CC. Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification. bioRxiv. 2023 May 18.  View on PubMed
  6. Clark IC, Fontanez KM, Meltzer RH, Xue Y, Hayford C, May-Zhang A, D'Amato C, Osman A, Zhang JQ, Hettige P, Ishibashi JSA, Delley CL, Weisgerber DW, Replogle JM, Jost M, Phong KT, Kennedy VE, Peretz CAC, Kim EA, Song S, Karlon W, Weissman JS, Smith CC, Gartner ZJ, Abate AR. Microfluidics-free single-cell genomics with templated emulsification. Nat Biotechnol. 2023 Nov; 41(11):1557-1566.  View on PubMed
  7. Demaree B, Delley CL, Vasudevan HN, Peretz CAC, Ruff D, Smith CC, Abate AR. Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia. Nat Commun. 2021 03 11; 12(1):1583.  View on PubMed
  8. Peretz CAC, McGary LHF, Kumar T, Jackson H, Jacob J, Durruthy-Durruthy R, Levis MJ, Perl A, Huang BJ, Smith CC. Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. Blood Adv. 2021 03 09; 5(5):1437-1441.  View on PubMed
  9. McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2019 08; 9(8):1050-1063.  View on PubMed

Go to UCSF Profiles, powered by CTSI